S SCHOLAR ROCK HLDG CORP
| Market Cap | $5.75B |
| P/E Ratio | — |
| Forward P/E | -23.31 |
| Dividend Yield | — |
| Beta | 0.69 |
| 52W Range | $24.47 - $50.01 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $958.00K | 21,762 | Add 20.50% |
Insider Trading
| Insider Name of the company insider who made the trade 30 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Mo QatananiCHIEF SCIENTIFIC OFFICER | Sale | 200 | $48.48 | $9.70K | 23 Feb 2026 | 25 Feb 2026 |
| Mo QatananiCHIEF SCIENTIFIC OFFICER | Sale | 7,427 | $46.94 | $348.64K | 23 Feb 2026 | 25 Feb 2026 |
| Mo QatananiCHIEF SCIENTIFIC OFFICER | Sale | 857 | $47.86 | $41.01K | 23 Feb 2026 | 25 Feb 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 200 | $48.48 | $9.70K | 23 Feb 2026 | 25 Feb 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 857 | $47.86 | $41.01K | 23 Feb 2026 | 25 Feb 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 7,427 | $46.94 | $348.64K | 23 Feb 2026 | 25 Feb 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 7,989 | $46.53 | $371.71K | 17 Feb 2026 | 19 Feb 2026 |
| Parlavecchio CarynCHRO | Sale | 9,035 | $46.53 | $420.38K | 17 Feb 2026 | 19 Feb 2026 |
| Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 4,157 | $46.53 | $193.42K | 17 Feb 2026 | 19 Feb 2026 |
| Ho JunlinGENERAL COUNSEL | Sale | 9,580 | $46.53 | $445.74K | 17 Feb 2026 | 19 Feb 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 12,779 | $46.85 | $598.75K | 22 Jan 2026 | 23 Jan 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 2,119 | $45.87 | $97.19K | 22 Jan 2026 | 23 Jan 2026 |
| Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 5,798 | $44.48 | $257.88K | 16 Jan 2026 | 21 Jan 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 8,406 | $44.48 | $373.88K | 16 Jan 2026 | 21 Jan 2026 |
| Parlavecchio CarynCHRO | Sale | 6,600 | $44.48 | $293.55K | 16 Jan 2026 | 21 Jan 2026 |
| Ho JunlinGENERAL COUNSEL | Sale | 8,016 | $44.48 | $356.53K | 16 Jan 2026 | 21 Jan 2026 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 13,112 | $45.20 | $592.61K | 14 Jan 2026 | 16 Jan 2026 |
| Vaishnaw AkshayPresident of R&D | Sale | 20,438 | $42.70 | $872.70K | 13 Jan 2026 | 15 Jan 2026 |
| Hallal DavidChief Executive Officer | Sale | 57,450 | $42.70 | $2.45M | 13 Jan 2026 | 15 Jan 2026 |
| Woods KeithChief Operating Officer | Sale | 16,746 | $42.70 | $715.05K | 13 Jan 2026 | 15 Jan 2026 |
| Sinha VikasChief Financial Officer | Sale | 16,755 | $42.70 | $715.44K | 13 Jan 2026 | 15 Jan 2026 |
| Peng Katie | Sale | 726 | $43.88 | $31.85K | 16 Dec 2025 | 18 Dec 2025 |
| Peng Katie | Sale | 280 | $44.63 | $12.50K | 16 Dec 2025 | 18 Dec 2025 |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 136,462 | $45.21 | $6.17M | 04 Dec 2025 | 05 Dec 2025 |
| AKKARAJU SRINIVAS | Buy | 12,400 | $40.18 | $498.23K | 07 Oct 2025 | 16 Dec 2025 |
| AKKARAJU SRINIVAS | Buy | 4,403 | $40.97 | $180.39K | 07 Oct 2025 | 16 Dec 2025 |
| AKKARAJU SRINIVAS | Buy | 12,796 | $39.31 | $503.01K | 07 Oct 2025 | 16 Dec 2025 |
| AKKARAJU SRINIVAS | Buy | 80,863 | $38.68 | $3.13M | 06 Oct 2025 | 07 Oct 2025 |
| AKKARAJU SRINIVAS | Buy | 13,748 | $39.52 | $543.32K | 06 Oct 2025 | 07 Oct 2025 |
| AKKARAJU SRINIVAS | Buy | 18,414 | $37.89 | $697.71K | 06 Oct 2025 | 07 Oct 2025 |
Frequently Asked Questions
What is SRRK stock price today?
SCHOLAR ROCK HLDG CORP (SRRK) is currently trading at $50.01. The stock has a 52-week range of $24.47 to $50.01 and a market capitalization of $5.75B.
Is SRRK a good stock to buy in 2026?
SCHOLAR ROCK HLDG CORP has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +62.9%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling SRRK stock?
There have been 30 insider transactions for SRRK in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has SRRK stock performed over the past year?
SCHOLAR ROCK HLDG CORP (SRRK) has returned +62.9% over the past 12 months. The stock traded between $24.47 and $50.01 during this period, and is currently at $50.01.
Which hedge funds own SRRK (SCHOLAR ROCK HLDG CORP)?
1 tracked hedge funds currently hold SRRK in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is SRRK's market cap and valuation?
SCHOLAR ROCK HLDG CORP (SRRK) has a market capitalization of $5.75B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is SRRK's revenue and profitability?
SCHOLAR ROCK HLDG CORP reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 0.69.
What sector is SRRK in and who are its biggest institutional holders?
SCHOLAR ROCK HLDG CORP (SRRK) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.